Clinical Trial

RA Capital's major investment extends Karyopharm's runway, but future funding is now directly tied to the outcome of its pivotal endometrial cancer trial.

A new Phase 2 trial is testing an inhaled version of a key IPF drug, aiming to reduce severe side effects and transform treatment for the fatal lung disease.

With over AUD$1M in sales from its first MDMA batch, Cortexa is validating Australia's pioneering move to legalize psychedelic-assisted therapy.

Sydnexis's eye drop trial shows high efficacy in children 3-12, positioning it as a potential first-of-its-kind FDA-approved drug for myopia.

With key trial enrollment complete, Pyxis Oncology refines its cancer drug MICVO for safety and prepares for pivotal data under a new, seasoned CEO.

Interna Therapeutics, Oxford, and the Gates Foundation team up on a novel intranasal siRNA spray to prevent COVID, tested in a human challenge trial.

With a promising non-opioid drug and new leadership known for major deals, Persica Pharmaceuticals is poised to revolutionize back pain treatment.

RenovoRx sets a key update call, juggling early RenovoCath device sales with its pivotal Phase III pancreatic cancer trial, a beacon for patients.

IntraBio's landmark FDA submission for levacetylleucine offers the first glimmer of an approved therapy for the devastating rare disease Ataxia-Telangiectasia.

The National Bleeding Disorders Foundation taps celebrity power for a live event, aiming to spotlight underdiagnosed conditions and transform advocacy.

Biotech firm Humacyte raises $20M to accelerate sales of its FDA-approved Symvess® and fund crucial trials for new hemodialysis applications.

A novel drug designed to eliminate stubborn cancer proteins enters human trials, offering a new strategy for ALK+ lung cancer patients facing resistance.

With pivotal trials advancing, key FDA alignment, and a strong cash position, Taysha Gene Therapies charts a clear path toward a potential breakthrough.

Annovis Bio's new trial for buntanetap uses an AI-powered Apple Watch app to track symptoms, aiming for more precise data in the race for a cure.

A new biotech spins out with a novel drug class aiming to provide healthier, more durable weight loss and combat cancer-related wasting syndrome.

A new $7 million deal will use a digital marketplace to deliver 16 million doses of a life-saving antibiotic to children in Burkina Faso. But can it work?

Biotech firm ProMIS Neurosciences reveals novel vaccine data for ALS and Parkinson's, using a platform that selectively targets only toxic proteins.

With a massive $68.7M seed round and novel T-cell engager tech, Shanghai's Excalipoint is pioneering a new model for rapid drug development.

A novel drug mimicking exercise aims to solve a major problem with today's weight-loss meds: muscle loss. Atrogi's ATR-258 has entered a key human trial.

SAB Biotherapeutics' public offering fuels late-stage trials for its promising T1D drug, SAB-142, aiming to change the treatment landscape.